Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
3/25/2025
Growing Awareness and Expanding Treatment Options for Sleep Disorders ...
3/25/2025
Hengrui and Elevar Face Second FDA Rejection for Liver Cancer Combo Th...
3/24/2025
Elevation Oncology to Discontinue Development of CSPC-licensed EO-3021
3/24/2025
HBM Enters into Global Strategic Deal with AstraZeneca for Next-Gen Th...
3/24/2025
AstraZeneca Announces $2.5B Investment in China
3/24/2025
CDE Seeks Public Comments on Draft ICH M11 Clinical Protocol Template
3/24/2025
Heng Ren Partners Calls for $8.9B Cash Distribution from Sinovac and ...
3/21/2025
Innovent and Hutchmed's FRUSICA-2 Study Achieves Primary Endpoint
3/21/2025
Rhythm Pharma Regains Rights to Obesity Drug in China
3/21/2025
Henlius' HER2-Targeting Antibody HLX22 Granted FDA Orphan Drug Designa...
3/21/2025
Hengrui's Ivarmacitinib Secures First Approval in China for Ankylosing...
3/21/2025
NHSA Releases Its 2024 Statistical Bulletin on Healthcare Security De...
3/21/2025
Gilead's Trodelvy Receives Second Approval in China
3/21/2025
Huadong Medicine's HDM1002 Advances to Phase III Clinical Trials
3/21/2025
Junshi's Toripalimab Receives 11th Approval in China
3/21/2025
NMPA Approves Hutchmed's Tazverik for r/r Follicular Lymphoma in China
3/21/2025
Recent Executive Moves
3/20/2025
Grand Pharma Advances Phase III Trial of ITM-11 in China
3/20/2025
Chinese Government Issues Notice on Strengthening Drug Traceability Co...
3/20/2025
State Council Issues the Opinion on Enhancing TCM Quality and Promotin...
3/19/2025
Hengrui Initiates Phase 2/3 Trial Combining SHR-A2102 and Adebrelimab ...
3/19/2025
EU Chamber Urges China to Balance Drug Procurement Priorities amid Pri...
3/19/2025
MSD Expands Public Health Efforts in China Following HPV Vaccine Appro...
3/19/2025
Shanghai Breaks Ground on National Emergency Medical Center
3/19/2025
These 12 Chinese Companies Are Poised to Transform CRISPR Gene-Editing...
3/19/2025
China's Healthcare Sector in 2025: Anti-Corruption and Beyond (CR)
3/19/2025
Severe Decline in County Market in 2024, Possible Rebound in 2025, wit...
3/17/2025
HBM and Insilico Enter Strategic Deal to Advance AI-Driven Antibody Di...
3/17/2025
BeiGene and Amgen Launch Phase 1 Trial of Tarlatamab + YL201 in China
3/17/2025
China Suspends Imports of Five APIs from Kyowa Hakko Bio's Hofu Plant
Page:
3
/
354
Total number of articles:
10618
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit